Comparison of Nedaplatin- and Cisplatin-Based Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer Patients: A Propensity Score Analysis

Abstract

The clinical outcome of this cohort of patients with locally advanced cervical cancer treated with CCRT did in no way provide support for the use of nedaplatin in place of cisplatin in chemoradiation and demonstrated no equivalence of the 2 drugs. Cautions should be taken for the replacement among platinum complexes in cancer treatment.

Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial

“…Experiences from several randomized trials found that the standard therapy for cervical carcinoma recommended by NCCN guidelines is platinum-based concurrent chemoradiotherapy, of which the most recommended is cisplatin. A retrospective study (9) found that compared with cisplatin, nedaplatin treatment expressed a higher relapse rate, lower OS, but non-significant difference in grade 3-4 toxicities. According to its observation, nedaplatin was not supported as an alternative to cisplatin in chemotherapy.…”

“…However, there is only one retrospective study comparing the efficacy and safety of nedaplatin against cisplatin in cervical cancer treatment (9). Compared with cisplatin, nedaplatin treatment expressed a higher relapse rate, lower overall survival, but non-significant difference in grade 3-4 toxicities.…”

Comparison of survival, acute toxicities, and dose–volume parameters between intensity‐modulated radiotherapy with or without internal target volume delineation method and three‐dimensional conformal radiotherapy in cervical cancer patients: A retrospective and propensity score‐matched analysis

“…However, Li et al did not support the use of nedaplatin in place of DDP in the treatment of patients who received CCRT. 45 DDP + 5FU and DDP + tegafur regimens had a higher incidence of HT than DDP + PTX in our study. Patients who experienced HT during chemotherapy were likely to receive less chemotherapy, which might explain why a higher chemotherapy completion rate was associated with a lower incidence of HT.…”

A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer

“…They did not support the use of nedaplatin in CCRT for cervical cancer. 13 Japanese researchers Kagabu et al. 14 found no significant difference in toxicity between cisplatin- or nedaplatin-based postoperative CCRT for cervical cancer.…”

“… 10 , 11 , 12 Li et al. 13 retrospectively analyzed 155 cervical cancer patients who received nedaplatin or cisplatin-based CCRT during radiotherapy. They concluded that patients who received nedaplatin had a higher recurrence rate than those who received cisplatin.…”